Silbi Insurance in Korea: Can Foreigners Enroll?

The claim that long-stay foreigners cannot buy Korean private actual-loss medical insurance (실손의료보험, “silbi”) is simply wrong. A foreigner with an alien-registration number is identifiable to Korean insurers, and companies operate foreigner verification and contract-management systems — KB Insurance, for one, documents verifying foreign customers by the name and number on the ARC or domestic residence-report card.

What silbi actually reimburses

The self-pay portion, split by whether NHIS covers the treatment

NHIS-covered20% self-pay

Not covered30% self-pay

One correction before anything else, though: there is no statutory “three requirements” — ARC + NHIS + the right visa — that guarantees silbi acceptance. Alien registration matters for identification, and NHIS status shapes how claims pay, but final acceptance is each insurer’s underwriting call across age, health history, occupation, and stay circumstances.

And the timing matters in 2026: the 5th generation of silbi launched on May 6, 2026. New contracts are written on 5th-gen terms; the large population of existing 4th-gen holders — many foreigners among them — manage their current contracts and the non-covered surcharge system. This guide covers both, plus the parts that are specifically foreign: identity matching, NHIS interplay, and cross-border edges.

Gate one is not nationality — it is being identifiable as a policyholder

At contract time the insurer verifies the real name, birth date, alien-registration or residence-report number, address, and contact details of the policyholder and insured. The foreigner-specific failure mode is name mismatch: KB’s guidance requires the uppercase English name and registration number exactly as printed on the ARC, and warns that verification can fail where the lawful stay period has lapsed or the Ministry of Justice database cannot confirm the person.

If your passport, ARC, telecom, and bank records spell your name three different ways, fix that before the insurance application — it is the same identity-consistency problem that trips foreigners at banks, transplanted to insurance.

NHIS is not a substitute for silbi — it is silbi’s reference point

Silbi does not pay medical bills independently. The structure is layered: NHIS pays the covered (급여) portion first; silbi then reimburses, per policy terms, your actual out-of-pocket — the covered co-payment plus eligible non-covered (비급여) costs. The insurance association describes silbi in exactly those terms: a complement to NHIS co-payments and non-covered costs.

Two precise statements follow:

• Maintaining normal NHIS status — employee, regional, or dependent — is central to managing medical costs. (Sort your NHIS position first; silbi comes second.)
• But “no NHIS, no silbi contract” is not the law. Contract acceptance and claim mechanics are separate questions.

The practically sharper issue is treatment that bypasses NHIS. Where care was not covered by NHIS or proper benefit procedures were not followed, silbi terms have applied a separate, lower reimbursement ratio to the whole cost rather than the normal covered/non-covered split — a recent Supreme Court case confirms a clause paying 40% of actual costs in that situation. Note the correction to a common error: this is not a universal “50%” rule; the ratio lives in each generation’s and product’s terms, with 40% the prominently documented structure.

There is no visa-based rate card

In practice, long-settled statuses (F-5, F-6, F-4) often make contract administration simpler, and E-7 professionals or D-8 investors with normal registration, residence, and income are routine candidates. But formalizing that into a table —

F-5 = auto-approved / E-7 = conditional / D-2·E-9 = declined

— has no basis in any published underwriting standard. Insurers assess age, medical history, current treatment, occupational risk, and identity verifiability per product, and reserve the right to decline — KB’s current silbi products state exactly that. Likewise, “your visa must have 12+ months remaining” is not an industry-wide legal threshold. The genuine boundary case is short-term visitors (C-3 and similar) without alien registration: for them, travel insurance or visitor medical products are the realistic instruments, not long-term domestic silbi.

4th generation: covered and non-covered deliberately separated

The 4th generation (sold from July 2021) split the product: the base contract covers 급여, a rider covers 비급여, with representative self-pay ratios set at 20% for covered and 30% for non-covered costs at introduction.

Simple-ratio illustrations: ₩1,000,000 of eligible covered co-payment → roughly ₩800,000 reimbursed; ₩1,000,000 of eligible non-covered costs → roughly ₩700,000. Outpatient care carries per-visit minimum deductibles by hospital type, so never just multiply every bill by 80%/70%. The 3rd generation’s “big three” non-covered items — manual therapy, non-covered injections, MRI — sit inside the 4th gen’s managed non-covered rider.

The number that matters most on 4th gen: last year’s non-covered claims

The non-covered premium differential began applying in July 2024, keyed not to your hospital bills but to non-covered claims the insurer paid you in the prior year:

Prior-year non-covered claims paid	Next renewal, non-covered premium
₩0	Discount
Under ₩1,000,000	Unchanged
₩1,000,000–1,500,000	+100%
₩1,500,000–3,000,000	+200%
₩3,000,000 or more	+300%

Read the +300% correctly: a ₩15,000/month non-covered rider premium in the top band becomes roughly 4× the base for that portion (100% base + 300% surcharge) — not ₩15,000 × 3 as a total. And two mitigations: the surcharge touches only the non-covered rider premium, not the whole policy, and the band is recalculated every year on the trailing twelve months — it is not a permanent mark. Serious-illness special-calculation categories and long-term-care grades 1–2 are exempt from the differential.

The expat-specific lesson: if you use manual therapy, non-covered injections, or MRI freely “because insurance pays,” compute the true TCO including next year’s premium — the reimbursement and the surcharge are one system.

2026 new enrollees calculate on the 5th generation

Since May 6, 2026, new silbi sales are 5th generation — so writing a “4th-gen enrollment strategy” for new buyers is out of date the day it is published. The 5th gen re-partitions non-covered care into severe versus non-severe, tightening self-pay on non-severe non-covered services while strengthening protection for severe illness, and the FSC projects premiums about 30% below 4th-gen levels.

For existing 4th-gen holders the live question is whether to keep the current contract (with its surcharge mechanics) — a generation-comparison decision that deserves its own follow-up guide.

Underwriting cares about your medical history, not your passport

Silbi is a high-loss-ratio product, which makes health disclosure the real gate. Recent examination findings, hospitalizations and surgeries, diagnoses and medications all feed acceptance decisions — KB’s current simplified-issue silbi, for instance, asks about re-examination findings within 3 months, hospitalization/surgery within 2 years, and cancer history within 5 years, and still reserves final refusal to company standards.

Foreigners get no disclosure discount. If a question covers treatment you received in your home country, it must be answered truthfully — omitting material history because translation is inconvenient sets up contract rescission or claim disputes later. Answering the application accurately is worth far more than saving a few thousand won of premium.

NHIS subscriber types are not silbi payout grades

Employee subscriber, regional subscriber, and dependent are NHIS contribution categories. They do not map to different silbi reimbursement rates (80%/70%/50% folklore). What silbi asks is whether the treatment ran through normal NHIS benefit procedures and what you actually paid. An F-6 spouse covered as a dependent and a self-paying regional subscriber with normal NHIS benefits are, for silbi claim purposes, judged by the same policy terms. The rational order: settle the household’s NHIS structure first, then layer silbi on top.

Claims run on documents — Korean ones

The claim file is about proving actual medical costs: claim form, ID, hospital payment receipts, plus — by amount and condition — prescriptions, diagnosis certificates, and itemized bills, per the insurance association’s standard list.

Two foreigner-specific clarifications. Korean insurers assess claims on Korean-language medical records — you generally do not need an English diagnosis certificate for a domestic silbi claim (that document is for your home-country insurer, a different errand). And use your own Korean bank account for payouts, with your registered identity consistent across bank and insurer — name mismatches at payout are avoidable errors.

Departure and visa changes: manage the contract, don’t abandon it

A status change (E-7 → F-5) neither upgrades your silbi automatically nor voids it. What does demand a review: long departures, ARC cancellation, or loss of NHIS status — at which point continuing to pay premiums may no longer make economic sense, because silbi fundamentally reimburses treatment at domestic medical institutions, and industry guidance confirms 2nd–4th generation products do not cover overseas medical costs. Anyone relocating abroad long-term should re-divide the roles of Korean silbi, international health insurance, and home-country coverage before leaving — not after the first foreign hospital bill.

The three-layer design for a foreign resident

The clean mental model for medical-cost defense in Korea:

1. NHIS — the state layer carries baseline covered-care risk.
2. Silbi — reimburses actual residual costs: covered co-payments and eligible non-covered care.
3. Lump-sum diagnosis policies (cancer, stroke, cardiac) — defend income interruption and living costs, not hospital bills.

Silbi is layer two, no more and no less. So the first question in any foreigner’s silbi decision is not “which visa do you hold?” but four better ones: how long will you live in Korea, what is your NHIS status, what is your health history, and how much non-covered care do you actually use? The insurer is pricing verifiable identity, health risk, and contract continuity — and you should be pricing the medical costs that remain after NHIS. Where those two numbers meet is your silbi decision.